Dickson Lauren, Menter Alan
J Drugs Dermatol. 2017 Feb 1;16(2):177-179.
The use of monoclonal antibodies against interleukin (IL)-12 and -23, such as ustekinumab, has considerably reduced the disease burden in many patients with moderate to severe psoriasis. Reversible posterior leukoencephalopathy syndrome (RPLS) is a neurologic disorder that has been documented with increased frequency with the use of systemic and biologic agents. We report a case of a 58-year-old man with psoriasis who presented with confusion and memory difficulties after being on treatment with ustekinumab for over six years. Imaging with CT and MRI revealed mild parenchymal edema with the typical appearance and distribution of RPLS, confirming the diagnosis of this condition. This case reports the second case of RPLS associated with ustekinumab treatment, with the only other known case reported during clinical trials. With the increasing use of biologics in patients with moderate to severe psoriasis, it is critical that clinicians are cognizant of this potential associated adverse event.
J Drugs Dermatol. 2017;16(2):177-179.
.使用抗白细胞介素（IL）-12和-23的单克隆抗体，如优特克单抗，已在许多中度至重度银屑病患者中显著减轻了疾病负担。可逆性后部白质脑病综合征（RPLS）是一种神经系统疾病，使用全身性和生物制剂后其发生频率有所增加。我们报告一例58岁银屑病男性患者，在接受优特克单抗治疗六年多后出现意识模糊和记忆障碍。CT和MRI成像显示有轻度脑实质水肿，具有RPLS的典型表现和分布，证实了该病的诊断。本病例报告了第二例与优特克单抗治疗相关的RPLS病例，另一例已知病例报告于临床试验期间。随着生物制剂在中度至重度银屑病患者中的使用增加，临床医生认识到这种潜在的相关不良事件至关重要。
《皮肤药物学杂志》。2017年；16（2）：177 - 179。
